Portfoliotracker

Rezolute, Inc.

RZLT · NASDAQCM · Healthcare Biotechnology 14/100 E

3,580 $
▼ −0,075 (−2,05 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 14:32
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score14 / 100 Market cap375 mil. $ P/E– Forward P/E-8,0 P/S– P/B4,4 EV/EBITDA– Dividend yield– FCF yield-19,59 % EPS-0,76 $ Net margin0,0 % Return on equity-66,9 % Beta0,62 Debt / equity0,01
52-week range 1,07 to 11,17
3-month average volume1,7 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Employees
63
Country
United States
Fiscal year end
30. 6.
Data since
14. 1. 2013

Explore further

Similar companies LRMRTRVIELDNTARAANNX

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account